According to the U.S. Agency of Health Care Policy and Research in 2005, there
are 46 million Americans who smoke or 21% of the U.S. population. As a result of
solid evidence demonstrating the numerous detrimental effects of smoking and the
rising national healthcare costs, research have focused on finding new ways to
aid in smoking cessation. Varenicline was recently approved by the FDA in 2006
for smoking cessation and is covered by most insurance plans including Medicaid
and Medicare. Therefore, patients and providers alike need a readily available
tool to use in clinics to guide management and decision-making. This pamphlet is
designed for patients who are motivated to quit smoking and want to learn more on
different smoking aid therapies, especially about the differences between the two
oral medications, Bupropion and Varenicline. The pamphlet also includes useful,
reliable websites and the national quitline phone number for the patient who is
seeking more counseling, detailed information on nicotine replacement therapies,
and self-help strategies to quit smoking. (The nicotine replacement therapies
are listed in order of risk of addictiveness with patches at least risk and nasal
spray at most risk.
The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.
New Medicines to Help You Stop Smoking.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.